We are live on ! Find out more
JANX icon

Janux Therapeutics
JANX

54 hedge funds and large institutions have $362M invested in Janux Therapeutics in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,082% more call options, than puts

Call options by funds: $201K | Put options by funds: $17K

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

29% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 14

13% more funds holding

Funds holding: 48 → 54 (+6)

0.08% less ownership

Funds ownership: 73.01% → 72.94% (-0.08%)

2% less capital invested

Capital invested by funds: $370M → $362M (-$7.41M)

Holders
54
Holders Change
+6
Holders Change %
+12.5%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
18
Reduced
14
Closed
5
Calls
$201K
Puts
$17K
Net Calls
+$184K
Net Calls Change
-$421K

Top Buyers

1
BI
BVF Inc
California
+$33.7M
2
Citadel Advisors
Citadel Advisors
Florida
+$3.51M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$3.21M
4
Millennium Management
Millennium Management
New York
+$1.39M
5
Cerity Partners
Cerity Partners
New York
+$814K

Top Sellers

1
EC
EcoR1 Capital
California
-$45.3M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.04M
3
VIA
Vident Investment Advisory
Georgia
-$671K
4
Morgan Stanley
Morgan Stanley
New York
-$201K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$154K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$103M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$60.1M -$1.04M -77,848 -2%
BI
3
BVF Inc
California
$48.7M +$33.7M +2,521,268 +159%
O
4
OrbiMed
New York
$33.7M – – –
Citadel Advisors
5
Citadel Advisors
Florida
$25.1M +$3.51M +262,548 +14%
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$25M +$3.21M +240,262 +13%
BlackRock
7
BlackRock
New York
$14.2M +$801K +59,943 +5%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$10.7M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$9.04M -$143K -10,665 -1%
EC
10
EcoR1 Capital
California
$5.37M -$45.3M -3,385,896 -88%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$4.48M +$303K +22,640 +6%
SB
12
Samsara BioCapital
California
$4.28M – – –
State Street
13
State Street
Massachusetts
$3.95M +$454K +33,961 +11%
Northern Trust
14
Northern Trust
Illinois
$2.22M +$632K +47,319 +34%
JP Morgan Chase
15
JP Morgan Chase
New York
$1.82M +$318K +23,779 +18%
Millennium Management
16
Millennium Management
New York
$1.64M +$1.39M +104,143 +305%
WP
17
Woodline Partners
California
$1.63M – – –
Cerity Partners
18
Cerity Partners
New York
$723K +$814K +60,933 New
N
19
Nuveen
North Carolina
$697K +$172K +12,842 +28%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$630K -$561 -42 -0.1%
DekaBank Deutsche Girozentrale
21
DekaBank Deutsche Girozentrale
Germany
$571K – – –
Charles Schwab
22
Charles Schwab
California
$547K +$9.74K +729 +2%
Squarepoint
23
Squarepoint
New York
$330K +$195K +14,613 +111%
RhumbLine Advisers
24
RhumbLine Advisers
Massachusetts
$318K -$949 -71 -0.3%
Swiss National Bank
25
Swiss National Bank
Switzerland
$271K -$56.1K -4,200 -16%
1
2 3

JANX Hedge Fund Activity: Q2 2023 in Review

54 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q2 2023, worth a combined $362M — down 2% from $370M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new JANX positions and 5 closed out — a net gain of 6 holders — while 18 added to existing stakes and 14 trimmed.

The largest buyer was BVF Inc, adding an estimated $33.7M. The largest seller was EcoR1 Capital, cutting an estimated $45.3M.

  • 54 institutional investors held Janux Therapeutics (JANX) as of Q2 2023, up from 48 in Q1 2023.
  • Funds reported $362M of Janux Therapeutics stock for Q2 2023, down 2% quarter-over-quarter.
  • 11 funds opened new Janux Therapeutics positions in Q2 2023 and 5 closed out, a net change of +6 holders.
  • The largest Janux Therapeutics buyer in Q2 2023 was BVF Inc, an estimated $33.7M added.
  • The largest Janux Therapeutics seller in Q2 2023 was EcoR1 Capital, an estimated $45.3M sold.

Based on aggregated 13F filings for Q2 2023.